Home » Topics » Hematologic, BioWorld Science

Hematologic, BioWorld Science
RSS

Akzo Nobel to transfer Arixtra to Sanofi-Synthelabo

Jan. 13, 2004

NCX-4016 reaches primary efficacy endpoint in phase IIa PAOD study

Jan. 12, 2004

Improved profile of TRA-418 possibly due to dual activity

Jan. 5, 2004

FR-181157 shows potent PGI2 agonist activity and good pharmacokinetic profile

Dec. 30, 2003

France is first country to approve oral thrombin inhibitor

Dec. 30, 2003

The Medicines Company acquires cangrelor from AstraZeneca

Dec. 29, 2003

Phase II results support efficacy of NovoSeven in trauma

Dec. 29, 2003

TGN-167 successfully completes phase I trial

Dec. 23, 2003

Enrollment completed in European rhATIII study

Dec. 19, 2003

Ximelagatran superior to warfarin in preventing VTE after total knee replacement

Dec. 19, 2003

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 20, 2026.
ALN-5288 lowers tau levels in preclinical models
BioWorld Science
Pathological tau accumulation is a key driver of neurodegeneration in Alzheimer’s disease (AD) and other tauopathies such as progressive supranuclear palsy....
Dual FAAH/MAGL inhibition targets Alzheimer’s disease hyperexcitability
BioWorld Science
Reduced endocannabinoid signaling has been linked to neuronal hyperexcitability in Alzheimer’s disease (AD), suggesting that dual inhibition of fatty acid amide...
Capital remains selective in ‘barbell’ biotech market
BioWorld
Signs of recovery are emerging in the biotechnology investment sector, although investors across Asia say that capital is flowing selectively to companies that...
PSB-229 reduces plaque burden in Alzheimer’s models
BioWorld Science
Pyroglutamate-modified amyloid-β (pE3-Aβ) is a highly pathogenic Aβ species that accumulates within amyloid plaques and contributes to aggregation,...